Literature DB >> 21833670

A Bayesian population analysis of the development of type 2 diabetes in the offspring of diabetic parents.

C W Lin1, J H Warram, P Veng-Pedersen.   

Abstract

Disease progression of type 2 diabetes (T2D) has received considerable attention, but little is known about the disease development of T2D. The purposes of this study were to identify disease development variables (DDV) for development of T2D and to compare corresponding models for disease development. All subjects included in this study were the offspring of diabetic parents and were followed up to 25 years. Repeated fasting blood samples were collected during the follow-up. Longitudinal data of four DDVs, namely fasting blood glucose (FBG), fasting serum insulin (FSI), homeostatic model assessment of insulin resistance (HOMA-IR) and body mass index (BMI) were recorded and compared. According to the diabetes status at the end of the follow-up, the data analysis involved a progressor group of 25 subjects, and a non-progressor group of 127 subjects. The temporal changes in the four DDVs over the time course of the disease development were evaluated by a single-slope and a dual-slope population-based Bayesian model. A dual-slope model based on FBG was found to be the best disease development model. For non-progressors, the FBG baseline stayed at 69.2 [66.5, 72.1] mg/dl (Bayes estimate [95% Bayesian credible set]) and increased with age by a rate of 0.227 mg/dl [0.149, 0.3] per year. For the progressors, the FBG increase with age the same rate as non-progressors and started to have an additional increase of 2.27 [0.505, 4.52] mg/dl per year, starting 8.73 [-10.8, -6.93] years before the diagnosis of T2D. No significant longitudinal increasing or decreasing temporal pattern was found for FSI, HOMA-IR and BMI by the population-based Bayesian approach. The proposed model, which enables a quantitative, time-based evaluation of the development of T2D in this higher risk population, may be used to quantify the effect of interventions/prevention strategies such as drug treatment and lifestyle changes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833670     DOI: 10.1007/s10928-011-9208-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  23 in total

1.  A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

Authors:  Willem de Winter; Joost DeJongh; Teun Post; Bart Ploeger; Richard Urquhart; Ian Moules; David Eckland; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-22       Impact factor: 2.745

2.  Analysis of metabolic progression to type I diabetes in ICA+ relatives of patients with type I diabetes.

Authors:  D Bleich; R A Jackson; J S Soeldner; G S Eisenbarth
Journal:  Diabetes Care       Date:  1990-02       Impact factor: 19.112

Review 3.  Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance.

Authors:  K S Polonsky; J Sturis; G I Bell
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

4.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

Authors:  C Weyer; C Bogardus; D M Mott; R E Pratley
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

5.  Risk factors for NIDDM in white population. Paris prospective study.

Authors:  M A Charles; A Fontbonne; N Thibult; J M Warnet; G E Rosselin; E Eschwege
Journal:  Diabetes       Date:  1991-07       Impact factor: 9.461

6.  Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

Authors:  C Weyer; P A Tataranni; C Bogardus; R E Pratley
Journal:  Diabetes Care       Date:  2001-01       Impact factor: 19.112

Review 7.  The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.

Authors:  S Del Prato; A Tiengo
Journal:  Diabetes Metab Res Rev       Date:  2001 May-Jun       Impact factor: 4.876

Review 8.  Epidemiology of non-insulin-dependent diabetes mellitus and its macrovascular complications. A basis for the development of cost-effective programs.

Authors:  J H Warram; J Kopczynski; H U Janka; A S Krolewski
Journal:  Endocrinol Metab Clin North Am       Date:  1997-03       Impact factor: 4.741

9.  Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.

Authors:  B C Martin; J H Warram; A S Krolewski; R N Bergman; J S Soeldner; C R Kahn
Journal:  Lancet       Date:  1992-10-17       Impact factor: 79.321

10.  Analysis of PK/PD risk factors for development of type 2 diabetes in high risk population using Bayesian analysis of glucose-insulin kinetics.

Authors:  Chih-Wei Lin; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-09-16       Impact factor: 2.745

View more
  1 in total

1.  Long-term consequences for offspring of paternal diabetes and metabolic syndrome.

Authors:  Benigno Linares Segovia; Maximiliano Gutiérrez Tinoco; Angeles Izquierdo Arrizon; Juan Manuel Guízar Mendoza; Norma Amador Licona
Journal:  Exp Diabetes Res       Date:  2012-11-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.